FDA approval of co-targeting BRAF and EGFR in colorectal cancer

April 8, 2020

FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation


January 26, 2012

Prahallad A*, Sun C*, Huang S*, Di Nicolantonio F*, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012 Jan 26;483(7387):100-3. doi: 10.1038/nature10868. PubMed PMID: 22281684. *Equal contribution